PNGM Financial Statements From 2010 to 2026

PNGM Stock  USD 0.0001  0.00  0.00%   
Er Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Er Therapeutics' valuation are provided below:
Market Capitalization
5.8 K
There are over ninety-two available fundamental measures for Er Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to verify Er Therapeutics' latest fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself in the future. As of the 3rd of February 2026, Enterprise Value is likely to grow to about 2.3 M, while Market Cap is likely to drop about 1.4 M.
Check Er Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Er Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 205.2 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. PNGM financial statements analysis is a perfect complement when working with Er Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with PNGM Stock
Check out the analysis of Er Therapeutics Correlation against competitors.
To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.

Er Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets283.4 K487.1 K394.8 K
Slightly volatile
Total Current Liabilities308.4 K616.4 K496.4 K
Pretty Stable
Accounts Payable387 K368.6 K309 K
Slightly volatile
Cash302318549
Slightly volatile
Total Liabilities308.4 K616.4 K496.4 K
Pretty Stable
Total Current Assets302318571
Slightly volatile
Common Stock48.1 K66.4 K55.2 K
Slightly volatile
Property Plant Equipment498.5 K474.8 K397.7 K
Slightly volatile

Er Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative205.2 K331.3 K274.3 K
Slightly volatile
Total Operating Expenses230.5 K358 K297 K
Slightly volatile

Er Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock34.5 K21.1 K31.2 K
Slightly volatile
Net Borrowings41.2 K24.9 K23.5 K
Pretty Stable
Other Cashflows From Financing Activities13.4 K15 K16.4 K
Slightly volatile
Capital Expenditures82.2 K78.3 K65.6 K
Slightly volatile
Change To Operating Activities30.2 K28.8 K24.5 K
Slightly volatile
Total Cash From Financing Activities110.7 K98.2 K112.6 K
Slightly volatile
Change To Netincome129.8 K123.6 K103.5 K
Slightly volatile
Change To Liabilities88.5 K170.4 K137.8 K
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables192.2 K183.1 K189.9 K
Slightly volatile
Capex To Depreciation254242251
Slightly volatile
ROIC23.2926.228.6002
Slightly volatile
Payables Turnover0.0690.07760.0847
Slightly volatile
Cash Per Share0.00.02.0E-4
Slightly volatile
Days Payables Outstanding3.4 K3.8 K4.2 K
Slightly volatile
Income Quality0.290.30.3289
Slightly volatile
Current Ratio0.02530.02664.9218
Slightly volatile
Average Receivables5.9 K6.6 K7.2 K
Slightly volatile
Interest Debt Per Share0.00320.00510.0053
Very volatile
Debt To Assets0.430.720.7718
Slightly volatile
Days Of Payables Outstanding3.4 K3.8 K4.2 K
Slightly volatile
Ebt Per Ebit0.690.780.8484
Slightly volatile
Quick Ratio0.02530.02664.9218
Slightly volatile
Cash Ratio0.00280.0034.5351
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.151.0368
Pretty Stable
Debt Ratio0.430.720.7718
Slightly volatile

Er Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 M1.5 M1.4 M
Slightly volatile
Enterprise Value2.3 M1.4 M1.7 M
Very volatile

About Er Therapeutics Financial Statements

Er Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how PNGM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Er Therapeutics is a strong investment it is important to analyze Er Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Er Therapeutics' future performance. For an informed investment choice regarding PNGM Stock, refer to the following important reports:
Check out the analysis of Er Therapeutics Correlation against competitors.
To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Diversified Metals & Mining sector continue expanding? Could PNGM diversify its offerings? Factors like these will boost the valuation of Er Therapeutics. Anticipated expansion of PNGM directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Er Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Return On Assets
(0.95)
Investors evaluate Er Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Er Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Er Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Er Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Er Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Er Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.